Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Melatonin Therapy Modulates Cerebral Metabolism and Enhances Remyelination by Increasing Pdk4 in a Mouse Model of Multiple Sclerosis Publisher



Ghareghani M1, 2 ; Scavo L3, 4 ; Jand Y5 ; Farhadi N2 ; Sadeghi H6 ; Ghanbari A2 ; Mondello S7, 8 ; Arnoult D4 ; Gharaghani S9 ; Zibara K3, 10
Authors
Show Affiliations
Authors Affiliations
  1. 1. CERVO Brain Research Center, Quebec City, QC, Canada
  2. 2. Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
  3. 3. Platform of Research and Analysis in Sciences and Environment (PRASE), Lebanese University, Beirut, Lebanon
  4. 4. INSERM U 1197, Laboratory of Stem Cells, Transplantation and Immunoregulation, Villejuif, France
  5. 5. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
  7. 7. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
  8. 8. Oasi Research Institute – IRCCS, Troina, Italy
  9. 9. Laboratory of Bioinformatics and Drug Design, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
  10. 10. Biology Department, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon

Source: Frontiers in Pharmacology Published:2019


Abstract

Metabolic disturbances have been implicated in demyelinating diseases including multiple sclerosis (MS). Melatonin, a naturally occurring hormone, has emerged as a potent neuroprotective candidate to reduce myelin loss and improve MS outcomes. In this study, we evaluated the effect of melatonin, at both physiological and pharmacological doses, on oligodendrocytes metabolism in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Results showed that melatonin decreased neurological disability scores and enhanced remyelination, significantly increasing myelin protein levels including MBP, MOG, and MOBP. In addition, melatonin attenuated inflammation by reducing pro-inflammatory cytokines (IL-1β and TNF-α) and increasing anti-inflammatory cytokines (IL-4 and IL-10). Moreover, melatonin significantly increased brain concentrations of lactate, N-acetylaspartate (NAA), and 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR). Pyruvate dehydrogenase kinase-4 (PDK-4) mRNA and protein expression levels were also increased in melatonin-treated, compared to untreated EAE mice. However, melatonin significantly inhibited active and total pyruvate dehydrogenase complex (PDC), an enzyme under the control of PDK4. In summary, although PDC activity was reduced by melatonin, it caused a reduction in inflammatory mediators while stimulating oligodendrogenesis, suggesting that oligodendrocytes are forced to use an alternative pathway to synthesize fatty acids for remyelination. We propose that combining melatonin and PDK inhibitors may provide greater benefits for MS patients than the use of melatonin therapy alone. Copyright © 2019 Ghareghani, Scavo, Jand, Farhadi, Sadeghi, Ghanbari, Mondello, Arnoult, Gharaghani and Zibara.